Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease.
Wang G, Li Y, Xiong C, Benzinger TLS, Gordon BA, Hassenstab J, Aschenbrenner AJ, McDade E, Clifford DB, Libre-Guerra JJ, Shi X, Mummery CJ, van Dyck CH, Lah JJ, Honig LS, Day G, Ringman JM, Brooks WS, Fox NC, Suzuki K, Levin J, Jucker M, Delmar P, Bittner T, Bateman RJ; DIAN‐TU Study Team.
Wang G, et al. Among authors: fox nc.
Alzheimers Dement. 2024 Apr;20(4):2698-2706. doi: 10.1002/alz.13735. Epub 2024 Feb 23.
Alzheimers Dement. 2024.
PMID: 38400532
Free PMC article.